Chronic lymphocytic leukemia (CLL) represents the most prevalent adult leukemia.
Introduction
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common leukemia, with an incidence rate of 2-6 cases per 100,000 people per year. 1 The median survival is highly variable with some patients exhibiting an indolent natural history whereas others develop aggressive disease with a survival of less than 2-3 years.
Genomic features such as IGHV mutational status, and p53 mutations (reviewed in 2 ). These patients all display poorer outcomes, with a markedly reduced survivals compared with patients with normal genomic features or good-risk (reviewed in 4 ). Of all prognostic factors examined in CLL, patients with mutated or deleted p53 respond very poorly to standard therapies that mainly act through mechanisms relying on an intact p53 pathway. Identifying therapies that circumvent p53
is therefore a priority for the treatment of this high-risk population. Attempts to intensify chemotherapy beyond fludarabine/alkylator-based combinations have been pursued with enhanced toxicity but little evidence of clinical benefit. As with many other types of cancers, treatment outcomes of CLL patients with chemotherapy-based approaches reached a plateau with no improvements in survival or hints of cure in even a subset of patients. This review will focus on how the clinical application of therapeutic monoclonal antibodies over the past decade has impacted the therapeutic approach to CLL and point to potential opportunities in the future with other targeted therapies currently being explored.
History of Monoclonal Antibodies in B-cell Malignancies
Monoclonal antibodies have a fixed effector cell binding region (Fc) and a variable region with affinity toward a specific antigen. Antibodies can mediate cytotoxicity toward tumor cells via both direct and indirect mechanisms based upon the target. Direct cytotoxicity of tumor cells can occur though transmembrane signaling, and recruitment of effector cells (NK cells, macrophage, neutrophils) that mediate antibody-dependent cell cytotoxicity (ADCC) and complement that mediates compliment-dependent cellular cytotoxicity (CDC). Indirect cytotoxicity can occur by interfering with both a tumor cell's interaction with the microenvironment-generated survival signal and with its binding to soluble factors that enhance tumor cell survival. Given the specificity of antibodies for a single antigen and the multiple mechanisms by which they can mediate cytotoxicity, antibody-based cancer therapy was seen as a potential "silver bullet" therapy for CLL, particularly if the antigen is selectively expressed on B-cells. Numerous target antigens offered the opportunity to selectively target B-cells, including CD19, CD37, CD20, and idiotype. Murine antibodies derived from mouse plasma cell hybridoma cells directed toward these targets were the first-generation agents evaluated in multiple clinical studies in the 1980's. These studies were impaired by production issues that limited antibody supply, diminished antibody activity toward the tumor cell, and development of human antibody-mouse antibody (HAMA) reactions with repeated administration. As a consequence, very modest activity with essentially all murine antibody-based treatments was observed, limiting the development of this modality.
Technologic advances allowing engineering of mouse-derived antibodies including a minimal mouse component of the variable complementarity-determing region (CDR) in the final product (chimeric or humanized) represented a major advance for this modality.
In general, chimeric and humanized therapeutic antibodies directed toward human B-cell antigens mediate improved ADCC and CDC compared to their murine counterparts.
Additionally, chimeric and humanized antibodies generally lack HAMA even on repeated administration. Concurrent with advances in chimeric and humanization technologies were improvements in the ability to produce larger amounts of antibodies. These advances fostered the rebirth of antibody-based therapeutics, impacting treatment of many diseases including CLL. This review will summarize evaluations of antibody and peptide therapies that directly target CLL cells that are either approved or under clinical investigation at this time (Table 1) .
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Rituximab

Rituximab Target and Mechanism of Action
Rituximab is a chimeric murine/human antibody directed against CD20. CD20 is expressed relatively selectively on B cells from the pre-B cell stage until post-germinal cells differentiate to become plasma cells. CD20 knock-out mice demonstrate normal B cell development and function, but CD19-induced calcium responses and B cell receptor (BCR) signaling are significantly altered.
5 Unlike other antigens, CD20 is neither shed nor internalized in resting normal B cells. 6 These data support CD20 as an ideal target for antibody based therapy in mature B-cell malignancies.
Rituximab was the first approved therapeutic antibody for the treatment of cancer.
Not surprisingly, the majority of mechanism of action studies of therapeutically utilized antibodies come from pre-clinical studies with rituximab. As with most IgG1 therapeutic antibodies, rituximab can mediate CDC, ADCC, and direct apoptosis with a cross-linking antibody ( Figure 1 ).
7
Extensive investigation of each mechanism has been pursued in lymphoma and CLL. While CDC is relevant to rituximab-mediated cytotoxicity in some Finally, several groups have demonstrated that rituximab can mediate both caspasedependent and -independent apoptosis in vitro (reviewed in 27 ) and in vivo 28 . Apoptosis appears to be the most important mechanism of action in CLL and involves the activation of the p38 mitogen-activated protein kinase, a pathway that requires an intact p53 gene, and caspase 9 cleavage. 7-9 Ofatumumab, a second-generation fully humanized anti-CD20 that recognizes a different CD20 epitope than rituximab, has similar ADCC, stronger CDC and requires cross-linking to induce direct apoptosis similar to riutximab.
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For personal use only. on November 12, 2017. by guest www.bloodjournal.org From GA101 binds with high affinity to the CD20 epitope and, as a result, induction of ADCC is 5-100 times greater than with rituximab. [31] [32] [33] [34] Type II anti-CD20 antibodies such as B1
and GA101 promote direct apoptosis without a cross-linking antibody. 35 Other differences between type I (rituximab, ofatumumab) and type II (GA101, B1) anti-CD20
antibodies lie predominately in their ability to redistribute CD20 into plasma membrane lipid rafts. 36 Type II anti-CD20 antibodies do not segregate CD20 into lipid rafts and are very effective at activating a caspase-independent, lysosomal-dependent mechanism of death that is dependent upon homotypic adhesion. 35 The relevance of this observation in vivo among CLL patients receiving type II CD20 antibody therapy remains unexplored.
Early Rituximab Studies and Single Agent CLL Trials
While the phase III pivotal approval study of rituximab in non-Hodgkin lymphomas (NHL) demonstrated promising clinical activity, the response among the 33 patients with SLL was modest, with only 12% of patients achieving a PR. 37 The combination of fludarabine, cyclophosphamide, and rituximab (FCR) has been extensively explored. A single-arm study of 300 previously untreated patients with progressive CLL from the MDACC reported an ORR of 95% with 72% of patients attaining a CR, 10% nodular partial remission (nPR), and 13% a PR. 47 The six-year OS and PFS) were 77% and 51%, respectively. 47 Toxicity in this study included predominately cytopenias and associated infection. Eight patients developed treatmentrelated myelodysplasia. A second study of 177 previously treated patients at this same institution was pursued using the same schedule of FCR. 48 The results of this study demonstrated a CRR in 25% of patients with an ORR of 73%. 48 The median time to progression was 28 months which varied significantly based upon response. Pentostatin is a nucleoside analog that has been suggested to be less myelotoxic than fludarabine while still active in CLL. This prompted a study in patients with previously 
Maintenance Rituximab in CLL
The use of maintenance rituximab is common in NHL. Contrasting with this approach, no randomized trials have been performed to determine if benefit is derived in CLL/SLL from extended maintenance therapy using rituximab. A phase II study of 75 previously untreated patients with CLL evaluated the efficacy of rituximab maintenance following treatment with fludarabine for 6 cycles. 
Rituximab in the Treatment of Autoimmune Complications
Autoimmune complications of CLL occur in 10 to 25% of patients during their disease course. Autoimmune hemolytic anemia (AIHA) is the most common, followed by immune thrombocytopenia (ITP). These occur both as an intrinsic process associated with the pathogenesis of CLL and as a result of treatment with purine analogues such as fludarabine. 60 Rituximab was initially described for the treatment of steroid-refractory pure red cell aplasia or AIHA 61 ; subsequently, the successful treatment of two patients with CLL who developed red cell aplasia with 375 mg/m 2 rituximab weekly for 2 weeks was described. 62 A series of 8 patients with CLL and steroid-refractory AIHA was treated with a combination of rituximab and dexamethasone, and all patients achieved a remission of their AIHA, with 5 patients achieving a Coombs-negative status.
Retreatment was also found to be successful. 63 In a series of 14 patients with CLL and AIHA treated with rituximab monotherapy, all but 2 patients had an increase in their hemoglobin levels after treatment. 64 Rituximab is effective in patients with chronic refractory ITP as well and is of interest in CLL specifically as fludarabine-related ITP is not responsive to steroids. Three patients who developed ITP while receiving fludarabine and who did not respond to treatment with steroids or IVIG were treated with weekly rituximab for four doses. All patients had rapid and dramatic improvements in their platelet counts, and the response durations were 6 months or greater for all three patients. 65 While randomized data demonstrating the exact benefit of rituximab in autoimmune complications is lacking, these data provide evidence for its effectiveness.
In the author's opinion, rituximab represents one of the more active therapies for the treatment of autoimmune complications of CLL not responding to initial steroid treatment.
Newer CD20 Antibodies for CLL
Ofatumumab
Ofatumumab is a newly-approved, human type I CD20 monoclonal antibody. In vitro, it has been demonstrated to mediate CDC against rituximab-resistant Raji cells and CLL cells with low expression of CD20. It appears to have greater potency in CDC than rituximab, as well as a slower off-rate and more stable CD20 binding. 29 Additionally, it appears to bind a different epitope of CD20 than rituximab. 30 A phase I/II study of ofatumumab in relapsed/refractory patients demonstrated that it is generally well tolerated, even at high doses and is active, with an ORR of 50%. Infusion-related adverse events are similar to those reported with rituximab and decrease following the first infusion. Infections were fairly common, occurring in 51% of patients, including one which was fatal. 66 A planned interim analysis of the seminal study of 138 patients treated with 8 weekly infusions of ofatumumab followed by 4 monthly infusions over a 24-week period has been reported. The patients included in this study were required to be refractory to at least one fludarabine-containing regimen and either refractory to at least 
all of which were grade 1 or 2. One-hundred-and-eighty-nine infectious events were reported, 74% of which were grade 1 or 2. Thirteen infections with onset during treatment resulted in death, including one reported case of progressive multifocal leukoencephalopathy (PML). 67 While the lack of CT scan monitoring of nodal disease in this study has been criticized, it is unclear that such monitoring add benefit in terms of predicting PFS to therapy in CLL 68, 69 . From this study and other data presented, it is unlear that ofatumumab offers relative to therapeutic benefit over the use of high dose rituximab previously reported 39, 40 . Only a randomized comparative study will be able to discern such a difference.
Combination studies are being done to enhance the therapeutic efficacy of ofatumumab. A study evaluating the combination of ofatumumab with fludarabine and cyclophosphamide (O-FC) was recently presented. Sixty-one previously untreated patients received either 500 mg or 1000 mg ofatumumab combined with fludarabine and cyclophosphamide every 4 weeks for a total of 6 courses. The CRR was 32% for patients who received 500 mg ofatumumab and 50% for those who received 1000 mg. The OR rates were 77% and 73% respectively. The most common grade 3-4 toxicities were infections, reported in 11 patients, and hematologic adverse events, including neutropenia in 29 patients, anemia in 8 patients, and thrombocytopenia in 9 patients. Grade 3-4 hemolytic anemia occurred in 3 patients. 70 Currently NCCN guidelines provide the recommendation for use of ofatumumab in previously treated CLL patients. 71 Clinical trials to define the activity of ofatumuamb in previously untreated CLL and in combination with most forms of chemoimmunotherapy explored with rituximab are ongoing. The actual scientific advance of ofatumumab over rituximab will require randomized Phase III trials.
GA101
GA101 is a type II glycoengineered humanized CD20 monoclonal antibody that binds CD20 in a completely different orientation than rituximab and over a larger surface area. 31 It initiates non-apoptotic cell death via an actin-dependent lysosome-mediated mechanism that is reliant on cell-to-cell contact. 32 73 The CD52 antigen is also expressed on tumor cells, particularly T-cell prolymphocytic leukemia (T-PLL) as well as CLL, hairy cell leukemia, NHL, and acute lymphoblastic leukemia. 74 Despite the frequent use of alemtuzumab in clinical trials, detailed mechanistic studies to elucidate specific pathways of cell killing have been hampered by the lack of cell lines expressing CD52. Thus, the mechanism of action of alemtuzumab remains to be completely clarified. Alemtuzumab can act through immunological mechanisms, such as CDC 75, 76 and/or ADCC by virtue of its IgG Fc region. 77, 78 It has also been shown that alemtuzumab can induce direct CLL cell death through a membrane raft-dependent mechanism. 79 Unlike rituximab, alemtuzumab has been shown to induce cell death in vitro in CLL cells through a mechanism that is independent of p53 status and caspase activation. 79 Moreover several in vivo clinical studies [80] [81] [82] report that alemtuzumab therapy is effective in subgroup of patients with high-risk cytogenetic markers (such as del(17p13.1)), which points to its unique mechanism of action.
Alemtuzumab Single Agent Activity
The dosing schedule of alemtuzumab was developed empirically using primarily clinical response as a surrogate endpoint in initial phase I studies. The intravenous (IV) dosing schedule currently used as the standard regimen for alemtuzumab therapy is comprised of a 2-hour intravenous (IV) infusion at a starting dose of 3 mg on day 1, 10 mg on day 2, and 30 mg three times weekly for a total of 8-12 weeks.
The effectiveness of single-agent alemtuzumab in refractory/relapsed CLL patients has been demonstrated (reviewed in 83 ) . In this setting, alemtuzumab produced an ORR of 33 to 54%. In the majority of these studies, anti-tumor effects of alemtuzumab were more significant in blood and bone marrow than in lymph nodes (especially if larger than 5 cm). The reason for this differential response is not clear, although it has been postulated to be related to poor bioavailability of the drug in bulky sites causing a low saturation of the binding sites on the neoplastic cells' surface. Moreover, there may be variability in the immune effector mechanisms in lymph nodes compared with other sites.
Alemtuzumab was initially approved in 2001 as a consequence of the pivotal CAM 211 phase III study in which 93 patients with relapsed or refractory CLL who had failed prior therapy with fludarabine and an alkylating agent were treated with stepped-up dosing followed by 30 mg three times weekly for a total of 12 weeks. 84 The ORR was 33% (2% CR, 31% PR) and the median duration of response was 8.7 months. Given that the majority of patients treated with IV alemtuzumab experience infusional toxicity combined with the observation that subcutaneous (SC) alemtuzumab had comparable biological activity with diminished infusion-related events, interest in SC administration has progressively increased. In a phase II study by the GCLLSG, 80 103 patients with fludarabine-refractory CLL received at least one dose of alemtuzumab, administered subcutaneously at 30 mg three times weekly for up to 12 weeks. The ORR was 34% (4% CR, 30% PR). The median PFS was 7.7 months and the median OS was 19.1 months.
This trial confirmed earlier studies that alemtuzumab was effective for del(17p13.1) CLL.
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In studies involving patients with relapsed/refractory CLL treated with alemtuzumab, the most common adverse events were cytopenias and infections as a consequence of profound cellular immune suppression. Reactivation of Herpes virus including cytomegalovirus (CMV) were the most common opportunistic infections observed.
Prophylaxis against opportunistic infections together with monitoring for CMV reactivation is highly recommended in these patients. Recently, O'Brien et al. 85 demonstrated that the addition of valganciclovir 450 mg orally twice daily was highly effective for prophylaxis of CMV reactivation in patients receiving alemtuzumab. Our own approach is to administer bactrim (or equivalent) and anti-herpes antiviral 
Alemtuzumab as Consolidation Therapy for CLL
Given that alemtuzumab works best against blood and bone marrow disease, efforts to apply alemtuzumab as a consolidation approach occurred early in its development for over a year. 83 Therefore the development of these LCLs is probably due to proliferation of EBV positive B cells in severely immunocompromised patients.
Development of LCL represents a major concern in alemtuzumab treated patients, although fortunately it is not that common. The GCLLSG 90 reported the results of a phase III trial where patients responding to fludarabine-based induction therapy were randomized to receive IV alemtuzumab 30 mg 3 times weekly for a maximum of 12 weeks or observation. Of 21 evaluable patients, 11 were randomized to receive alemtuzumab. This study was prematurely closed because of severe infections in 7 of 11 patients in the alemtuzumab arm. The PFS was significantly improved for patients receiving alemtuzumab at a median follow-up of 21.4 months. The CALGB performed two studies administering alemtuzumab after fludarabine 91 or fludarabine and rituximab. 92 Both of these studies demonstrated the ability of alemtuzumab to improve response to treatment. 92 However, reactivation of CMV was observed in both studies and unacceptable infectious toxicity was observed in patients when alemtuzumab was administered following fludarabine and rituximab. A community-based clinical trial administering alemtuzumab after fludarabine and rituximab also noted problematic toxicity with combined chemoimmunotherapy. 93 Future attempts to explore this consolidation approach following chemoimmunotherapy regimens should allow an extended recovery time prior to administration of alemtuzumab. Consolidation with alemtuzumab should only be considered in the context of a clinical trial.
Alemtuzumab Combination Strategies in CLL
In an attempt to enhance the therapeutic activity observed with fludarabine-based regimens, alemtuzumab has been added to this modality by several investigators (reviewed in 83 ). These studies have, in general, demonstrated feasibility of administration with an acceptable toxicity profile. A phase III study comparing fludarabine combined with alemtuzumab (FluCAM) versus fludarabine alone was recently reported. 94 This study of 335 previously treated CLL patients receiving second line therapy demonstrated a higher ORR, CRR and PFS with the combination therapy.
Adverse events included cytopenias and infections and were similar between both treatment arms. The only toxicity uniformly associated with FluCAM was CMV reactivation in 8% of patients. 94 Attempts to further intensify this regimen with the addition of cyclophosphamide to FluCAM resulted in increased infectious morbidity. 95 Concomitantly, efforts to combine alemtuzumab with the FCR regimen were undertaken in both relapsed 96 and previously untreated high risk CLL 97 . While these studies demonstrated feasibility, it is unclear that any benefit was offered over the FCR-based 
Other Targets
Efforts to target other B-cell specific antigens are underway as part of clinical trials at this time. Table 2 with the potential to avoid the immunosuppressive effects of chemotherapy treatments.
Conclusions
Monoclonal antibodies represent an exciting addition to the growing armamentarium of agents used to treat CLL. 
